Titan Pharmaceuticals Inc. buy melinda
Start price
25.08.17
/
50%
€276.01
Target price
27.12.17
€568.26
Performance (%)
-20.59%
End price
27.12.17
€219.19
Summary
This prediction ended on 27.12.17 with a price of €219.19. The price of Titan Pharmaceuticals Inc. has decreased during the runtime of the prediction. Compared to the start price this resulted in a performance of -20.59%. melinda has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Titan Pharmaceuticals Inc. | - | - | - | - |
| iShares Core DAX® | -0.874% | 5.325% | 6.865% | 65.211% |
| iShares Nasdaq 100 | -0.381% | 1.979% | 25.696% | 90.325% |
| iShares Nikkei 225® | -1.676% | 1.952% | 41.443% | 80.623% |
| iShares S&P 500 | -0.655% | 2.069% | 21.405% | 70.737% |
Comments by melinda for this prediction
In the thread Titan Pharmaceuticals Inc diskutieren
pharma
SOUTH SAN FRANCISCO, Kalifornien. , 24. August 2017 / PRNewswire /: (NASDAQ Anwendung) hat heute bekannt gegeben , dass die Food and Drug Administration (FDA) die New Drug (IND) für seine Ropinirol Implantate zur Behandlung von Anzeichen und Symptomen der Parkinson-Krankheit zugelassen hat. Die Phase 1/2 der klinischen Studie bei Patienten in Kürze beginnen.
(Vom Mitglied beendet)
Stopped prediction by melinda for Titan Pharmaceuticals Inc.
Titan Pharmaceuticals Inc.
Start price
Target price
Perf. (%)
€4.17
24.10.20
24.10.20
€9.00
04.11.21
04.11.21
-65.11%
05.11.21
05.11.21
Titan Pharmaceuticals Inc.
Start price
Target price
Perf. (%)
€39.68
05.10.18
05.10.18
€81.18
22.10.18
22.10.18
44.72%
22.10.18
22.10.18
Titan Pharmaceuticals Inc.
Start price
Target price
Perf. (%)
€172.10
23.02.18
23.02.18
€194.83
22.03.18
22.03.18
22.58%
22.03.18
22.03.18
Titan Pharmaceuticals Inc.
Start price
Target price
Perf. (%)
€891.36
08.07.16
08.07.16
€1,298.9
09.01.17
09.01.17
-18.94%
09.01.17
09.01.17